Related Experiment Video
Updated: Mar 29, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.7K
Carbidopa levodopa enteral suspension.
Lauren C Seeberger1, Robert A Hauser2
1a Department of Neurology , University of Colorado , Denver , CO 80045 , USA.
Expert Opinion on Pharmacotherapy
|November 24, 2015
Summary
Continuous dopaminergic stimulation (CDS) is key for Parkinson's disease (PD) management. Carbidopa/levodopa enteral suspension offers significant improvements in motor fluctuations for advanced PD patients.
Area of Science:
- Neurology
- Movement Disorders
- Pharmacology
Background:
- Parkinson's disease (PD) treatment focuses on consistent, effective therapies.
- Continuous dopaminergic stimulation (CDS) mimics physiological dopamine release, crucial for PD management.
Purpose of the Study:
- To review interventions for motor fluctuations in advanced Parkinson's disease.
- To evaluate carbidopa/levodopa enteral suspension (Duopa) as a continuous therapy option.
Main Methods:
- Overview of deep brain stimulation (DBS), subcutaneous apomorphine infusion, and carbidopa/levodopa enteral suspension (Duopa).
- Focus on Duopa delivery via percutaneous gastrostomy with jejunum tube extension (PEG-J tube).
Main Results:
- Carbidopa/levodopa enteral suspension significantly improves motor fluctuations and "on" time compared to oral formulations.
- Reduces plasma levodopa variation, enhancing treatment consistency.
Conclusions:
- Carbidopa/levodopa enteral suspension provides motor fluctuation improvements comparable to DBS and apomorphine infusion.
- It is a valuable alternative for advanced PD patients unsuitable for or unresponsive to other continuous therapies.
Related Concept Videos
01:18Routes of Drug Administration: Enteral
8.3K
Medications can be administered through the enteral route using liquids, capsules, or tablets.
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
8.3K
01:18Drug Delivery: Enteral Route
2.5K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
2.5K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
212
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
212
01:11Oral Drug Delivery Systems: Delayed-Release Systems
144
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
144
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.7K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.7K